Boston's Watchman edges closer to US approval with feasibility study success
This article was originally published in Clinica
Executive Summary
Boston Scientific's Watchman device has been shown to reduce the risk of ischaemic stroke by 75% in a feasibility study, raising hopes that it will eventually be approved in the US. However, the FDA green light is still some time away – Boston is currently enrolling patients in a Phase III study to support approval. The company is anticipating FDA approval and US launch in 2013.